CKlife sciences announced its interim report for the year 2024, with unaudited attributable profit to shareholders of approximately HKD 1 million, a decrease of 97% compared to the same period last year. The company announced that it will not distribute interim dividends and is expected to record sales proceeds of approximately AUD 8.2 million from the sale of Balranald vineyard land and water permits in Australia after settlement. CKlife sciences focuses on the research and development of cancer therapy and early cancer detection programs, and invests in cancer diagnosis company Pharus to develop liquid biopsy technology. The performance of the company's health product business is stable, with a profit of HKD 156.4 million. However, the cumulative impact of high inflation rates continues to put pressure on cost structure. CKlife sciences will continue to make stable investments in the fields of medicine and diagnostics research, and is expected to expand its investment scale in the research field.

CKlife sciences announced its interim report for the year 2024, with unaudited attributable profit to shareholders of approximately HKD 1 million, a decrease of 97% compared to the same period last year. The company announced that it will not distribute interim dividends and is expected to record sales proceeds of approximately AUD 8.2 million from the sale of Balranald vineyard land and water permits in Australia after settlement. CKlife sciences focuses on the research and development of cancer therapy and early cancer detection programs, and invests in cancer diagnosis company Pharus to develop liquid biopsy technology. The performance of the company's health product business is stable, with a profit of HKD 156.4 million. However, the cumulative impact of high inflation rates continues to put pressure on cost structure. CKlife sciences will continue to make stable investments in the fields of medicine and diagnostics research, and is expected to expand its investment scale in the research field.